Skip to main content

Animations

MJFF Publications

4851 - 4860 of 6514 Results
Title
Year
  • Year
  • 2019
  • 2019
  • 2016
  • 2018
  • 2017
  • 2023
  • 2023
  • 2020
  • 2023
  • 2021
  • Summary Details
    OPEN
    Title: Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.jalz.2019.08.196
    Citation Count: 44
  • Summary Details
    OPEN
    Title: A novel approach to study markers of dopamine signaling in peripheral immune cells
    Journal Name: Journal of Immunological Methods
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.jim.2019.112686
    Citation Count: 23
  • Summary Details
    OPEN
    Title: White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration
    Journal Name: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.dadm.2016.03.001
    Citation Count: 93
  • Summary Details
    OPEN
    Title: Amnestic mild cognitive impairment individuals with dissimilar pathologic origins show common regional vulnerability in the default mode network
    Journal Name: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.dadm.2018.08.004
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Beyond L-DOPA: hope for Parkinson’s treatment and diagnosis
    Journal Name: EBioMedicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.ebiom.2017.09.009
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats
    Journal Name: Brain Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.brainres.2023.148381
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.celrep.2023.112448
    Citation Count: 35
  • Summary Details
    OPEN
    Title: BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s13311-020-00965-9
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s13311-023-01440-x
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
    Journal Name: Neurology and Therapy
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s40120-021-00246-3
    Citation Count: 16
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.